Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement
2021
Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) have long been recognized to cause hepatitis B virus (HBV) reactivation in individuals chronically infected with or previously exposed to HBV.1 Despite this knowledge, many patients treated with b/tsDMARDs experience HBV reactivation each year because of inconsistent screening.2.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI